<DOC>
	<DOCNO>NCT02605616</DOCNO>
	<brief_summary>Does novel drug decrease liver fat subject NASH NAFLD compare placebo</brief_summary>
	<brief_title>Use Novel Drug People With Non-alcoholic Steatohepatitis ( NASH ) Non-alcoholic Fatty Liver Disease ( NAFLD )</brief_title>
	<detailed_description>We propose combine voxel match magnetic resonance spectroscopy ( MRS ) magnetic resonance elastography ( MRE ) liver ( pre vs. post ) evaluate hepatic fat hepatic fibrosis . We also establish glucose tolerance status establish label oral glucose tolerance test ( OGTT ) ( 6,6 ²H2 glucose ) . Following baseline evaluation subject biopsy/MRE proven NASH randomize one two group treat either active drug ( AZ compound ) placebo 12 week ( plus minus 1 week ) . Subjects history suggestive non-alcoholic fatty liver disease ( NAFLD ) NASH invite participate . If meet criterion follow initial screen include study . OGTT , liver MRS , MRE repeat . Liver enzymes [ aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase ( ALP ) ] well safety test [ creatine phosphokinase ( CPK ) , thyroid stimulate hormone ( TSH ) , international normalize ratio ( INR ) , total bilirubin ] measure , monthly therapy one month follow therapy .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Age : 2175 Body Mass Index ( BMI ) 1940 kg/m^2 Subjects biopsy/MRE proven NASH [ MRS liver fat ≥ 5 % , elevate liver enzymes ALT &lt; 5x upper limit normal ( ULN ) ] . Subjects NAFLD MRE show F2 great fibrosis Subjects history suggestive NAFLD/NASH Total bilirubin must &lt; 1.5 x ULN INR must &lt; 1.3 baseline screening . TSH CPK within normal limit ( WNL ) screening . Subjects type 2 diabetes stable dos medication ( except pioglitazone ) control hyperglycemia baseline HbA1c 10 % low . Hemoglobin must great equal 12.0 male 11.0 female . Medications may affect glucose metabolism corticosteroid , opiate , barbiturate , anticoagulant . Subjects anemia , symptom suggestive undiagnosed illness , overt hepatic disease , stroke , Alzheimer 's disease , autoimmune hepatitis , alcoholism increase alcohol consumption ADA guideline . Any disorder may potentially impact outcome measure . Pregnant woman child . Subjects plan weight loss weight loss program . Subjects take TZD 's , Atazanavir , Indinavir , Ketoconazole , Valproic acid , Silybum marianum Valeriana officinalis .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>